Savara Stock Price Today NASDAQ: SVRA Quote, Market Cap, Chart

The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.

Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time. Provide specific products and services to you, such as portfolio management or data aggregation. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

News flow

All investments involve risk, and not all risks are suitable for every investor. The value of securities may fluctuate and as a result, clients may lose more than their original investment. The past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss in a down market. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing.

Based on 5 analysts giving stock ratings to SVRA in the past 3 months. Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases.

Savara Inc. Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Savara (SVRA – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday at $1.71.According to TipRanks, Fein is an analy… Wainwright reiterated a Buy rating on Savara (SVRA – Research Report), with a price target of $3.00. The company’s shares closed last Friday at $1.17.Fein covers the Health…

In the Morningstar Style Box, large-cap names what is the difference between yield and return for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days.

• The firm’s lead program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of autoimmune pulmonary alveolar proteinosis.
• Looking at another peer, we see that Sangamo Therapeutics Inc. price has dipped -2.40% on the day.
• 52 week low is the lowest price of a stock in the past 52 weeks, or one year.

Apex Crypto is not a registered broker-dealer or FINRA member and your cryptocurrency holdings are not FDIC or SIPC insured. Please ensure that you fully understand the risks involved before trading. Not all coins provided by Apex Crypto LLC are available to New York residents. Please visit /cryptocurrency to see a list of crypto available to trade. The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Webull Advisors is an Investment Advisor registered with and regulated by the SEC under the Investment Advisors Act of 1940. Registration does not imply a level of skill or training. Trades in your Webull Advisors account are executed by Webull Financial LLC, a member of the Securities Investor Protection Corporation . That means your assets are protected up to $500,000 in value, including $250,000 in any cash awaiting reinvestment.

Independent Director recently bought US$187k worth of stock

The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease.

Based on an average trading volume of 242,400 shares, the days-to-cover ratio is presently 4.0 days. Approximately 1.4% of the company’s shares are sold short. Market cap, also known as market capitalization, is the total market value of a company.

Industry Products

The 5 analysts offering 1 year price forecasts for SVRA have a max estimate of — and a min estimate of —. Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat’s FREE daily newsletter. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. What analysts recommend for SVRA stock, on a scale from 1 to 5. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Savara stock was originally listed at a price of $8.76 in Apr 28, 2017.

The dark blue line represents the company’s actual price. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

https://1investing.in/s in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates. See Jiko U.S. Treasuries Risk Disclosures for further details. Additional information about your broker can be found by clicking here.

According to analysts’ consensus price target of $2.50, Savara has a forecasted upside of 45.3% from its current price of $1.72. According to analysts, Savara’s stock has a predicted upside of 33.33% based on their 12-month price targets. Market cap is the total market value of a publicly traded company’s outstanding shares. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.

According to the current price, Savara is 160.75% away from the 52-week low. The high in the last 52 weeks of Savara stock was 2.85. According to the current price, Savara is 60.35% away from the 52-week high.

The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. A $0.55 per contract fee applies for certain options trades. High-growth stocks tend to represent the technology, healthcare, and communications sectors.

Live from Hong Kong, bringing you the most important global business and breaking markets news information as it happens. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

• Here are five of the best ways to profit from the AI boom.
• The past performance of a security, or financial product does not guarantee future results or returns.
• Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The company’s lead program, molgramostim nebulizer solution , is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis .

SVRA stock returns are also predicted based on historical data. An Overall Rank of 78 means that our comprehensive methodology rates Savara Inc. above 78% of stocks. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Our clearing firm Apex Clearing Corp has purchased an additional insurance policy. Similar to SIPC protection, this additional insurance does not protect against a loss in the market value of securities.

The average twelve-month price prediction for Savara is $2.50 with a high price target of $3.00 and a low price target of $2.00. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. DescriptionSavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company.